9 minutes read
Radiation therapy (RT) is a core component of oncology treatment in China — approximately 60–70% of cancer patients require radiation during their treatment course. China’s precision radiotherapy equipment is highly internationalized: the three major global brands Varian, Elekta, and Accuray dominate the mainstream market, while domestic brands like United Imaging are rising rapidly. TomoTherapy (helical tomotherapy) has approximately 57 installations, and high-end technologies like CyberKnife, Gamma Knife, and MR-Linac are widely available at top centers. For international patients, China not only offers advanced radiotherapy equipment of the same models and grades as those in Europe and North America, but typically at 1/3 to 1/5 of US pricing. This article walks through China’s complete precision radiotherapy technology landscape, technology selection by cancer type, leading centers, and the practical international patient pathway.
China’s Radiotherapy Equipment Internationalization
Linear accelerator market structure (June 2023–May 2024 winning bid share, 363 total units) [1]:
- Varian: 40.66%
- Elekta: 40.13%
- United Imaging (domestic): 12.28%
Major Chinese oncology hospitals use the same equipment models as top Western centers — you do not sacrifice equipment generation by coming to China.
Domestic high-end representatives:
- United Imaging uRT-linac 506c: launched 2018, the world’s first CT-integrated linear accelerator, cumulative installations of 40–50 units
- Users include Fudan Cancer, Sun Yat-sen Cancer Center, Peking Union Medical College, and Peking University Third Hospital
- In 2024 launched uLinac HalosTx ring accelerator and EternaTx large-bore model
TomoTherapy (Helical Tomotherapy)
Technical principle [2]:
- Manufactured by US-based Accuray
- Integrates spiral CT imaging with intensity-modulated radiation therapy
- 360° rotating fan beam delivery from the gantry
- Can treat multiple targets and long target volumes in a single treatment — TOMO’s greatest technical advantage
China installations [3]:
- As of 2024, approximately 57 TomoTherapy helical tomotherapy units nationwide
- Accuray Tomo C, designed for the Chinese Class B market, has received NMPA registration
- Accuray FY2024 financial report: China orders Q2 +44% YoY
Typical installation hospitals:
- Peking Union Medical College Hospital
- West China Hospital, Sichuan University
- Wuhan Union Hospital (Huazhong University of Science and Technology, Radixact 4th generation)
- Guangzhou Medical University Affiliated Cancer Hospital (launched February 2024)
- Hebei Yizhou Cancer Hospital
- Liaoning Cancer Hospital
Core differences between TomoTherapy vs IMRT/VMAT [4]:
- TomoTherapy delivers via helical fashion to treat ultra-long target volumes — such as craniospinal irradiation (CSI), total marrow irradiation (TMI), multiple brain/bone metastases
- Varian/Elekta linear accelerator VMAT is limited by 40×40 cm field; long targets require multi-isocenter joining
- Dosimetric studies show TomoTherapy often provides superior OAR (organ at risk) sparing (e.g., optic chiasm, salivary glands)
TomoTherapy’s best indications:
- Medulloblastoma craniospinal irradiation (CSI)
- Complex head and neck cancers (multiple targets + critical organ sparing)
- Multiple brain metastases
- Multiple bone metastases
- Total marrow irradiation (used as conditioning for hematopoietic stem cell transplantation)
- Re-irradiation (sites previously irradiated requiring repeat treatment with strict dosimetric constraints)
Other High-End Precision Radiotherapy Technologies
CyberKnife
Technical principle: robotic arm-mounted linear accelerator that delivers high-precision stereotactic body radiation therapy (SBRT) through real-time image tracking and image guidance.
China installations [5]:
- Peking Union Medical College Hospital installed CyberKnife S7 (7th generation) in 2022
- Tianjin Cancer Hospital, Liaoning Cancer Hospital, Foshan Fosun Chancheng Hospital, and others have M6
- Domestic RayerKnife received NMPA Class III certification in September 2024 — domestic substitution accelerating
Best indications:
- Extracranial SBRT small targets: spinal metastases, liver metastases, lung metastases, pancreatic cancer, prostate cancer
- Non-surgical intracranial alternatives: trigeminal neuralgia, cavernous sinus hemangioma
- Cases where lesion location is close to critical organs and traditional surgical risk is high
Gamma Knife
Technical principle: fixed-position 192 or 201 cobalt-60 radiation sources simultaneously focused on a small intracranial region for single high-dose stereotactic delivery.
China installations [6]:
- Domestic market share exceeds 90% (Da Yi Group and others)
- Listed in standard radiotherapy catalog in March 2023 — coverage expanded
Best indications (intracranial only):
- Brain metastases (single or few metastases)
- Acoustic neuroma
- Pituitary adenoma
- Trigeminal neuralgia
- Arteriovenous malformation (AVM)
- Cavernous sinus tumors
MR-Linac (Magnetic Resonance-Integrated Linear Accelerator)
Technical principle: MRI-guided real-time radiation therapy with far superior soft tissue contrast than CT guidance, enabling online adaptive replanning (adjusting plan to current anatomy at each treatment).
China installations [7]:
- Elekta Unity is the only NMPA-approved MRI linear accelerator in China (100% market share)
- 2019–2020 clinical trials at 5 institutions: Cancer Hospital CAMS, Shandong Cancer Hospital, Fudan Cancer, Sun Yat-sen Cancer Center, Sichuan Cancer Hospital
- Shandong Cancer Hospital had the first installation
- As of November 2023, over 15 hospitals in clinical use with cumulative >2,000 cases treated
- ViewRay MRIdian’s parent company filed bankruptcy in July 2023; not widely installed in China
Best indications:
- Abdominal and pelvic tumors with high soft tissue contrast dependency (pancreas, liver, prostate, kidney, cervix)
- Cases requiring adaptive radiotherapy (tumor position or size varies between treatments)
- Liver/lung SBRT with high respiratory motion management dependency
Decision Framework by Indication
| Clinical Scenario | Recommended Technology | Alternative |
|---|---|---|
| Medulloblastoma CSI | TomoTherapy | Proton (pediatric preferred) |
| Total body/marrow irradiation (TBI/TMI) | TomoTherapy | — |
| Multiple brain metastases (>3) | TomoTherapy / VMAT | Gamma Knife (few metastases) |
| Single brain metastasis | Gamma Knife / CyberKnife | SBRT |
| Complex head and neck cancer | TomoTherapy / IMRT | Proton (skull base / nasopharyngeal / re-irradiation) |
| Nasopharyngeal cancer | IMRT / VMAT (SYSUCC) | Proton/heavy ion (recurrent or high complication risk) |
| Liver SBRT | CyberKnife / MR-Linac | VMAT |
| Pancreatic SBRT | MR-Linac (adaptive advantage) | CyberKnife |
| Prostate SBRT | MR-Linac / CyberKnife | VMAT |
| Spinal metastasis SBRT | CyberKnife | VMAT |
| Pediatric brain tumors | Proton (Article 22) | TomoTherapy (low dose) |
| Re-irradiation | Proton / TomoTherapy | CyberKnife |
Top Chinese Radiotherapy Centers
Sun Yat-sen University Cancer Center Radiotherapy Department [8]
- Largest radiotherapy center in Asia
- 276 beds, 15 linear accelerators
- World-leading nasopharyngeal cancer radiotherapy
- Full indication coverage: IMRT, VMAT, SBRT, TOMO
Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS) Radiotherapy Department
- National Cancer Center
- Participated in Elekta Unity MR-Linac clinical trials
- Top comprehensive capability
Fudan University Shanghai Cancer Center Radiotherapy Department
- One of Shanghai’s largest cancer radiotherapy centers
- Equipped with United Imaging uRT-linac integrated accelerator
- Multiple MR-Linac and IMRT multi-center research
Peking Union Medical College Hospital Radiotherapy Department
- Equipped with TomoTherapy + CyberKnife S7
- Among the most comprehensive equipment portfolios in China
West China Hospital, Sichuan University Radiotherapy Department
- Largest radiotherapy center in southwest China
- Equipped with TomoTherapy
Peking University Cancer Hospital Radiotherapy Department
- Strong comprehensive capability
- Comprehensive equipment
Pricing
Comparison (based on international data + China estimates):
| Treatment | US All-Inclusive Cost (USD) | China Estimate |
|---|---|---|
| IMRT/VMAT complete course | $25,000–$80,000 | Approximately 1/5 to 1/8 of US |
| TomoTherapy complete course | $30,000–$90,000 | Similar to IMRT |
| CyberKnife SBRT | $20,000–$50,000 | Approximately 1/4 to 1/6 of US |
| Gamma Knife | $20,000–$40,000 | Approximately 1/3 to 1/5 of US |
| MR-Linac | $40,000–$100,000 | Approximately 1/4 to 1/6 of US |
| Proton therapy (Article 22) | $100K–$200K | China SPHIC ~$43K–$48K |
Core value: China’s advanced precision radiotherapy all-inclusive costs are typically 1/3 to 1/8 of US — economically significant for long-course radiotherapy (such as head and neck cancer 30–35 fractions).
Practical International Patient Pathway for Advanced Radiotherapy in China
Best-suited international patients:
- Long radiation therapy waiting time in home country (especially in Europe, where some countries have 4–12 week waits)
- Unaffordable radiation therapy costs in home country (out-of-pocket or uninsured)
- Specific technology unavailable in home country (such as no MR-Linac or TomoTherapy)
- Complex re-irradiation — China’s TOMO + proton combination advantage
Typical timeline:
| Phase | Duration |
|---|---|
| Pre-travel evaluation and document preparation | 4–6 weeks (remote) |
| Arrival + on-site evaluation + treatment plan formulation | 1–2 weeks |
| Actual radiation therapy (plan-dependent) | 1–7 weeks (SBRT 1 week; standard fractionation 5–7 weeks) |
| Early follow-up | 1–2 weeks |
Total time in China: typically 3–10 weeks (depending on treatment complexity)
Common Questions
Is China’s advanced radiotherapy equipment really at the same level as Western equipment? Yes. Varian + Elekta hold 80%+ market share in China — using the same equipment models as the West. Domestic high-end equipment from United Imaging has reached international first-tier level (especially the uRT-linac CT-integrated accelerator).
Is TomoTherapy better than conventional radiation therapy (IMRT/VMAT)? Depends on the cancer. TomoTherapy is meaningfully superior to VMAT in long target volumes, multiple lesions, complex head and neck, and re-irradiation scenarios. For single-lesion standard radiation therapy, VMAT is already sufficient.
When to choose MR-Linac? Abdominal and pelvic tumors with high soft tissue contrast dependency (pancreas, liver, prostate, kidney, cervix) + cases requiring adaptive radiotherapy (tumor position changes at each treatment).
How to choose between proton/heavy ion vs TomoTherapy? See Article 22. Briefly: pediatric, skull base, chordoma, recurrent re-irradiation prioritize proton/heavy ion; for most other cases, TomoTherapy / IMRT / VMAT are sufficient.
How does China’s CyberKnife compare for spinal metastasis treatment? On par with Western leading centers. Peking Union Medical College Hospital, Liaoning Cancer Hospital, and others have CyberKnife teams with extensive spinal SBRT experience.
Can I return home immediately after radiation therapy? Typically not — early radiation side effects (skin reaction, mucositis, fatigue, etc.) require 2–4 weeks of observation. Recommended to stay in China at least 2 weeks after radiation therapy completion for early follow-up.
Bottom Line
Core value of China’s advanced precision radiotherapy:
- International-grade equipment (Varian + Elekta + Accuray + Elekta Unity MR-Linac)
- Domestic high-end rising (United Imaging uRT-linac CT-integrated)
- 57 TomoTherapy + 15+ Elekta Unity MR-Linac + Gamma Knife / CyberKnife widely distributed
- Pricing approximately 1/3 to 1/8 of US
- Mature top centers: SYSUCC, CICAMS, Fudan Cancer, PUMC, West China, Peking University Cancer Hospital
Best-suited international patients:
- Long home-country radiation therapy wait
- Unaffordable home-country costs
- Requiring specific advanced technology (MR-Linac, TomoTherapy, etc.)
- Complex re-irradiation (TOMO + proton combination)
Total time in China: 3–10 weeks (plan-dependent)
If you’re considering advanced precision radiotherapy in China, MedCareInChina matches the best radiotherapy center and technology for your specific diagnosis — and clearly identifies expected timeline, cost, and long-term follow-up pathway.
→ Send your case to hello@medcareinchina.com
See Service & Refund Policy and Medical Disclaimer for service boundaries.
Sources
- China Linear Accelerator Market Share (June 2023–May 2024) — 363 winning bids: Varian 40.66%, Elekta 40.13%, United Imaging 12.28%. Source: Sina Finance https://finance.sina.com.cn/roll/2024-11-21/doc-incwusvs4775506.shtml
- TomoTherapy Technical Principle — Accuray manufactured, spiral CT + intensity-modulated RT integration. Source: Accuray FY2024 SEC filing https://www.sec.gov/Archives/edgar/data/0001138723/000095017024096978/aray-ex99_1.htm
- China TomoTherapy Installations — As of 2024 approximately 57 units. Installation hospitals include PUMC, West China, Wuhan Union, Guangzhou Medical University Affiliated Cancer Hospital, etc. Sources: Industry report https://health.ycwb.com/2024-02/18/content_52506819.htm ; Wuhan Union https://www.whuh.com/info/1021/13858.htm
- TomoTherapy vs VMAT Dosimetric Comparison — TOMO often superior in long targets, multiple lesions, and OAR sparing. Sources: TCR journal https://tcr.amegroups.org/article/view/26954/20104 ; Multiple brain metastasis study https://link.springer.com/article/10.1186/s13014-025-02742-4
- China CyberKnife Installations — PUMC 2022 installed S7; Tianjin Cancer, Liaoning Cancer, Foshan Fosun Chancheng installed M6; domestic RayerKnife NMPA Class III certification September 2024. Sources: PUMC https://www.pumch.cn/detail/32357.html ; RayerKnife https://www.vbdata.cn/1518987521
- China Gamma Knife — Domestic market share >90%; March 2023 listed in standard radiotherapy catalog. Source: VBData https://www.vbdata.cn/42761
- Elekta Unity MR-Linac China — 100% market share; 2023.11 CIIE disclosure: >15 hospitals in clinical use with cumulative >2,000 cases treated. Source: 36Kr https://www.36kr.com/p/957074272188038
- Sun Yat-sen University Cancer Center Radiotherapy Department — Largest in Asia (276 beds, 15 linear accelerators), world-leading nasopharyngeal cancer. Source: SYSUCC Radiotherapy http://sysucc.org.cn/flk
- United Imaging uRT-linac 506c — Launched 2018, world’s first CT-integrated linear accelerator. Source: Compiled hospital installation reports.
